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The promise of exploiting the specifi  city of the 
T cell response for treating cancer has been 
questioned. Immunotherapy may fail because 
(a) the cancer cells do not express MHC ap-
propriately, (b) a physical stromal barrier (1–5) 
produced by the host–cancer interaction pre-
vents access of immune eff  ectors to the cancer, 
(c) immune regulation prevents activation/
proliferation of eff  ector T cells, or (d) variants 
emerge during cancer progression that are no 
longer susceptible to specifi  c eff  ector mole-
cules or cells. Antigen (Ag)-specifi  c CTLs may 
kill cancer cells very eff   ectively even when 
they express low levels of Ag (6, 7). However, 
established tumors produced by cancer cells 
expressing high levels of Ag are cured by adop-
tively given CTLs, whereas tumors produced 
by cancer cells expressing low levels of Ag and 
treated similarly regress initially but then grow 
progressively because of the emergence of Ag 
loss variants (8, 9).
Our recent (8, 9) and present experiments 
show that targeting tumor stroma by adoptive 
CTL therapy is highly eff  ective for treating es-
tablished cancers. The success of CTL therapy 
depended on the destruction of stroma of tu-
mors produced by cancer cells expressing high 
levels of Ag. We suggested that the killing of 
stroma occurred because these stromal cells 
picked up suffi   cient Ag to cross-present it and 
be killed by CTLs. With the elimination of 
critical stroma, Ag-negative variant cancer cells 
in the tumor were also killed. If this is the 
case, then CTL therapy should also be eff  ec-
tive against tumors produced by cancer cells 
expressing low levels of Ag if the tumor stroma 
was loaded with suffi   cient cancer cell Ag.
Irradiation or chemotherapy causes apop-
tosis and necrosis of cancer cells; therefore, we 
tested whether these procedures could cause 
suffi   cient release of Ag from cancer cells ex-
pressing low levels of Ag to sensitize tumor 
stroma for killing by CTLs. For this objective, 
we developed a high affi   nity TCR tetramer 
for detecting minute quantities of the rele-
vant tumor-specifi  c peptide–MHC complexes 
(pMHCs) cross-presented by stromal cells. Indeed, 
either radiation or chemotherapy, given 2 d 
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before CTL therapy, sensitized cancer stroma for destruction 
by T cells so that the tumors were eradicated; i.e., variants did 
not grow out.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
High affi   nity TCR tetramers were used for fl  ow cytometry to 
visualize the presentation of the SIYRYYGL (SIY) peptide 
used as tumor-specifi  c Ag and presented on cell-surface Kb 
as pMHC, because wild-type TCR tetramers cannot detect 
this complex (unpublished data). The single-chain m67 TCR 
consisted of the wild-type 2C Vβ region, a 25-aa linker, and 
the mutant m67 Vα region fused to a C-terminal peptide that 
contained the recognition site for biotinylation by the BirA 
enzyme. Each biotin attaches to the single biotin-binding site 
on a streptavidin (SA) molecule that occurs as a homotet-
ramer and is chemically coupled to the fl  uorescent dye PE, 
thereby generating mTCR-tetramer–SA-PE (Fig. 1 a). The 
affi   nity of the engineered m67 TCR for the SIY-Kb complex 
is  16 nM, whereas the wild-type 2C TCR has >1,000-
fold lower affi   nity, similar to most other “natural” CD8-
  dependent TCRs reactive with peptide–self-MHC (10, 11). As 
shown in Fig. 1 b, diff  erences in peptide concentrations in 
the range of 0.1 nM to 1 μM could be clearly distinguished. 
The probe is specifi  c with minimal background binding to 
cells loaded with the irrelevant gp33 peptides at a 1-μM 
concentration (Fig. 1 b). Similar results were also observed 
in RMA-S cells (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20062056/DC1). SIY-Kb complexes 
were detected on MC57-SIY-Hi or on MC57-SIY-Lo cells. 
Complexes were not detected on parental MC57-Neo cells 
or on MC57-gp33-Hi cells that endogenously express high 
levels of irrelevant gp33 Ag (Fig. 1 c). Kk-positive PRO4L 
cancer cells expressing high levels of SIY but lacking Kb 
do not present the relevant SIY–pMHC complex on their 
cell surface (Fig. 1 c and Fig. S2). Cells stained with PE-
  conjugated SA (SA-PE) only or with an equimolar amount 
of an irrelevant m6 TCR tetramer were used as controls and 
exhibited background fl  uorescence intensity similar to that of 
the unstained cells (unpublished data). These results indicate 
that we have developed a reliable method to determine the 
levels of Ag–MHC complex on cell surfaces.
The CD11b+ cells comprised >20% of total cells in 
the 2-wk-old MC57 tumors. The CD11b+ cells largely ex-
pressed CD45, F4/80, and MHC class II molecules but not 
CD11c, and therefore represented tumor-associated macro-
phages that may present tumor-derived Ag (Fig. S3, available 
at http://www.jem.org/cgi/content/full/jem.20062056/DC1). 
To explore the kinetics of cross-presentation in vitro, we 
used J744 Kb macrophages, peritoneal exude cells (PECs), 
Jaws II dendritic cells, and purifi  ed tumor-derived CD11b+ 
stromal cells as APCs. As the source of Ag, cancer cells that 
were either necrotic (three serial freeze-thaw cycles) or apop-
totic (induced by sorbitol) were incubated with APCs at a 
1:1 ratio. Cross-presentation was determined by specifi  c tetramer 
staining after incubation for 2, 4, 10, or 12 h. Maximal cross-
presentation occurred at 4 h and decreased with very little 
Ag remaining on the surface of APCs after 10 or 12 h of 
co-culture (Fig. S4), suggesting that tumor-derived APCs 
  acquiring Ag from dead cancer cells in vivo might present 
the relevant pMHC complexes only transiently.
Tumor stroma from established MC57-SIY-Lo tumors 
was not stained by the TCR tetramer (Fig. 2 a). Also, the 
stromal cells from established MC57-SIY-Lo tumors were 
insensitive to lysis by specifi  c T cells (Fig. 2 c, left). We then 
tested whether radiation or chemotherapy caused a “bolus” 
of tumor Ag release from MC57-SIY-Lo cells suffi   cient for 
uptake and presentation by CD11b+ tumor stromal cells. 
High affi   nity TCR tetramers detected SIY-Kb complexes on 
CD11b+ stromal cells from the tumors of irradiated but not 
nonirradiated mice. To determine the time of maximal Ag 
cross-presentation by tumor-derived stroma in vivo, mice 
bearing 2-wk-old solid tumors were killed at 12 h and 1, 2, 
3, and 4 d after local radiation. As shown in Fig. 2 a, maximal 
Figure 1.  High affi  nity TCR tetramer binding. (a) Model of the 
SIY-Kb-specifi  c m67 TCR tetramer (see Results and discussion for details). 
(b) The TCR tetramer can detect SIY-Kb complexes on T2Kb cells artifi  cially 
loaded with peptide at the indicated concentrations as low as 0.1 nM. 
(c) SIY-Kb complexes were detected on MC57-SIY-Hi cells that express 
endogenously high levels of SIY Ag and MC57-SIY-Lo cells that express 
endogenously low levels of SIY Ag, but not on parental MC57-Neo or 
MC57-gp33-Hi cells that express endogenously high levels of irrelevant 
gp33 Ag. In addition, PRO4L-SIY-EGFP failed to be stained by the tetramers. 
Data are representative of two (b) or fi  ve (c) similar experiments. MFI, 
mean fl  uorescence intensity.JEM VOL. 204, January 22, 2007  51
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cross-presentation by MC57-SIY-Lo tumor stroma was 
found 2 d after irradiation and decreased thereafter with very 
little Ag remaining after 4 d. In contrast, SIY-Kb–specifi  c 
complexes were detected on CD11b+ stromal cells from a 
2-wk-old MC57-SIY-Hi tumor without irradiation (Fig. 2 b). 
CD11b+ stromal cells from a 2-wk-old MC57-gp33-Hi tu-
mor were negative, and there was no noticeable binding to 
CD11b+ stromal cells from MC57-gp33-Lo tumors after 
  irradiation (Fig. 2 b). Furthermore, MC57-SIY-Lo tumors 
were exposed to diff  erent doses of radiation, and the levels of 
SIY-Kb complexes were determined 2 d later. We found the 
highest levels of SIY-Kb complexes on the cell surface at a 
dose of 10 Gy, indicating that the increased cross-  presentation 
by CD11b+ stromal cells was radiation dose dependent 
(Fig. S5, available at http://www.jem.org/cgi/content/full/
jem.20062056/DC1). The stromal cells derived from MC57-
SIY-Lo cancer cells 2 d after irradiation were sensitized for 
destruction by CTLs, but stromal cells isolated 4 d after irra-
diation were not killed, consistent with the kinetics observed 
by staining (Fig. 2 c, left and middle). MC57-gp33-Lo stro-
mal cells were not killed by CTLs when isolated 2 d after 
  irradiation (Fig. 2 c, left and middle). MC57-SIY-Lo and 
MC57-gp33-Lo cancer cells were used as concurrent controls 
(Fig. 2 c, right).
We next determined whether radiation-induced sensiti-
zation of stroma from Lo-Ag tumors prevented escape of Ag 
Figure 2.  Local radiation of tumors leads to the time-dependent 
stromal sensitization in established cancer. (a) 2 × 106 MC57-SIY-Lo 
or MC57-gp33-Lo cells were injected s.c. into the fl  anks of C57BL/6 
Rag1−/− mice. Both cell lines express low levels of SIY or gp33 Ag. Where 
indicated, 15-d-old tumors were locally irradiated with 10 Gy. Tumors 
were excised at 12 h and 1, 2, 3, and 4 d. Single suspension cells were 
stained by APC-conjugated anti-CD11b antibody and m67 TCR tetramers. 
Cells were analyzed for tetramer staining by gating CD11b+ cells. (b) As 
concurrent controls, CD11b+ cells from locally irradiated MC57-gp33-Lo 
tumors were analyzed at 2 d after irradiation for tetramer staining. 
SIY-Kb–specifi  c m67 TCR tetramer-bound CD11b+ cells from a 2-wk-old 
MC57-SIY-Hi tumor but not those from a 2-wk-old MC57-gp33-Hi tumor 
are shown. (c) Effective sensitization of tumor-derived stroma by local 
irradiation of MC57-SIY-Lo tumors expressing low levels of SIY Ag. 2 but 
not 4 d after local irradiation, CD11b+ stromal cells purifi  ed from 2-wk-
old established MC57-SIY-Lo tumors were lysed by 2C CTLs in a 4.5-h 51Cr 
release assay. CD11b+ stromal cells purifi  ed from a 2-wk-old antigenically 
irrelevant MC57-gp33-Lo tumor were not lysed. MC57-SIY-Lo and MC57-
gp33-Lo cancer cells were used as controls. Data shown (a and b) represent 
one of two similar experiments. MFI, mean fl  uorescence intensity.52  INDUCED SENSITIZATION OF TUMOR STROMA | Zhang et al.
loss variants. As shown in Fig. 3, locally irradiating 14-d tu-
mors once with 10 Gy followed by T cell transfer 2 d, but not 
4 d, after irradiation led to complete eradication of well-
  established MC57-SIY-Lo tumors. These tumors, without 
irradiation, regularly escaped with an outgrowth of cancer 
variants after T cell therapy (unpublished data). Thus, the 
time interval between radiation and adoptive T cell therapy 
was crucial (Table I). Furthermore, MC57-SIY-Lo tumors 
growing in C3H Rag2−/− mice in which stroma is incapable 
of cross-presenting the tumor Ag were not rejected after 
  irradiation and CTL therapy (Table I). Single (10 Gy) or 
  repeated (2 × 10 Gy) local irradiation alone did not cure any 
of the mice. Thus, the radiation-induced eff  ect depended on 
sensitization and destruction of tumor stroma. We next tested 
whether the eff  ects observed after irradiation also applied to a 
chemotherapeutic agent, gemcitabine. Maximal loading of 
the MC57-SIY-Lo tumor stroma occurred at 2 d after drug 
treatment (Fig. 4 a), and complete rejection was achieved 
when T cells were transferred at 2 but not at 4 d after gem-
citabine treatment (Fig. 4 b and Table I).
Important work has been done on the synergy between 
immunotherapy and irradiation (references 12–15; for review 
see reference 16) or chemotherapy (references 14, 17, 18; for 
review see reference 19). However, unlike the present study, 
these studies have dealt with the induction of immune 
  response or with direct eff  ects of radiation or drugs on the 
killing of cancer cells. Recently, it was demonstrated that 
  radiation, by activating the mammalian target of Rapamycin 
pathway, could rapidly increase the intracellular pool of pep-
tides derived from rapidly degraded proteins and increase 
MHC class I expression and peptide presentation by the can-
cer cells, thereby increasing the sensitivity of cancer cells to 
Figure 3.  Local radiation of tumors promotes cancer eradication by 
CTLs. 2 × 106 MC57-SIY-Lo cells per cell line were injected s.c. into OT-1 
transgenic mice or a C3H Rag2−/− mouse, and the volume of the tumor (mm3) 
was measured every 3 d. After 14 d, the tumors were locally irradiated with 
10 Gy, followed by adoptive transfer of 5 × 106 preactivated 2C T cells at 
day 16 or 18. As controls, tumors were only treated at days 14 and/or 16 
with local irradiation using 10 Gy, or tumor-bearing mice only received 
adoptive transfer of 5 × 106 preactivated 2C T cells on day 16 but no 
  irradiation. Each symbol represents an individual mouse. Four independent 
experiments are shown, with each in a separate panel. In addition, a fi  fth 
experiment (not depicted) confi  rmed that repeated irradiation with 10 Gy 
on days 14 and 16 (20 Gy total dose) did not cure any of the mice (n = 3).
Table I.  Stroma and timing are critical for complete elimination of established tumors
Treatment Host Tumor 
stroma
Rejection of 
tumorsa
p-value
Irradiation + T cells 
  2 d later
OT-1 H-2b 12/12
Irradiation + T cells 
  4 d later
OT-1 H-2b 0/9 0.001b
Irradiation + T cells 
  2 d later
C3H Rag2−/− H-2k 0/9 0.001b
Gemcitabine + T cells 
  2 d later
OT-1 H-2b 7/8
Gemcitabine + T cells 
  4 d later
OT-1 H-2b 0/6 0.001c
Gemcitabine + T cells 
  2 d later
C3H Rag2−/− H-2k 0/6 0.001c
aData are pooled from seven independent experiments. Mice shown in Fig. 3 and Fig. 4 b are included in this pool of data.
bCompared, respectively, with the group OT-1 irradiation + T cells 2 d later.
cCompared, respectively, with the group OT-1 Gemcitabine + T cells 2 d later.JEM VOL. 204, January 22, 2007  53
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direct killing by T cells (15). This enhancement of direct kill-
ing may be important and necessary, but not suffi   cient, for 
treating large, established solid tumors (8, 9). Indeed, our 
current results show that the direct eff  ect of radiation on can-
cer cells is insuffi   cient to eradicate cancer unless the tumor 
stroma is sensitized for destruction by T cells. Thus, after a 
combination of local radiation treatment (or systemic drug 
treatment) and adoptive T cell transfer, established cancers 
regularly escaped as Ag-loss variants when the stroma (H-2k) 
was unable to cross-present the Ag, or when T cells were 
transferred at a time when the stroma was no longer  sensitized. 
In vitro, Ag loading of CD11b+ cells peaked after a few hours 
(Fig. S4), whereas in vivo, the loading and cross-presentation 
of tumor Ag by CD11b+ APCs peaked at 2 d after radiation 
or chemotherapy (Fig. 2 a and Fig. 4 a). The likely diff  erence 
is that, in vitro, APCs were fed with already apoptotic or ne-
crotic material, whereas in vivo, additional time is needed for 
apoptosis to occur after radiation or drug treatment before 
antigenic material is released. Our results do not address the 
question of whether the direct eff  ects of radiation or chemo-
therapy on tumor stroma additionally contribute to tumor 
rejection, but such a contribution has been indicated by an 
earlier study using a chemotherapeutic agent (20).
These results support the concept that the curative 
  combination of irradiation or chemotherapy and subsequent 
adoptive T cell immunotherapy of established solid tumors 
depends on the radiation or chemotherapeutic drugs releas-
ing tumor Ag from cancer cells in the tumor, followed by 
sensitization and destruction of tumor stroma. One might 
also argue that T cell–mediated destruction of cells cross-
  presenting Ag violates an important basic safety mechanism. 
If, for example, Ag from virally infected cells sensitized nor-
mal (uninfected) surrounding tissue, CD8+ T cell destruction 
of this tissue could be disastrous. However, the elimination 
of cells in proximity to infected cells could inhibit patho-
gen spread by sacrifi  cing a rim of the healthy tissue while 
still limiting tissue damage locally to the infected area (5). 
This is consistent with our fi  nding that destruction of cross-
  presenting tissue is completely Ag dose dependent. This point 
is furthermore made by recent fi  ndings showing that cross-
presentation of intracellular peptides by transfer through 
gap junctions is limited to a few neighboring cells (21, 22). 
  Although the spread of apoptotic and necrotic material from 
killed cancer cells most likely extends beyond neighboring 
cells, there was no destruction of normal stroma away from 
the tumor. Tumor stroma consists of nonmalignant cells, but 
this stroma is by no means a normal tissue. Tumor stroma 
contains activated fi  broblasts (23, 24), recently formed im-
mature and leaky capillaries, and many types of infl  ammatory 
cells comparable to a nonhealing wound (25). Ag pick-up 
and presentation is therefore likely to be very diff  erent in 
such a stroma. In fact, the advantage of our form of   stromal tar-
geting probably depends on not damaging or arresting stromal 
cells where there are no cancer cells.
The use of highly artifi  cial experimental models allowed 
us to reveal principles, components, and interactions that 
would not have been discovered in usual models because 
of the lack of comparable high affi   nity TCR tetramers. The 
transfected Ag is not a self-Ag but a tumor-specifi  c Ag; we 
believe that such Ags exist on the tumors and can be recog-
nized with autologous T cells. In our study, we treated 
2-wk-old established tumors in which the acute infl  ammation 
reaction of transplantation has vanished and which are virtu-
ally indistinguishable from nontransplanted autochthonous 
tumors by histopathologic examination (26). Therefore, al-
though our results still need to be confi  rmed in hosts bearing 
autochthonous tumors, there is no reason to assume that the 
principles and concepts developed in this study will not be 
Figure 4.  Treating tumors with gemcitabine leads to the time-
dependent stromal sensitization and helps achieve tumor eradication 
by CTLs. (a) 14 d after tumor challenge, the tumor-bearing mice were 
treated i.p. with 200 μg/g (body weight) gemcitabine. Tumor tissues 
were excised and dispersed, and single suspension cells were stained by 
APC-conjugated anti-CD11b and m67 TCR tetramer 1, 2, 3, and 4 d after 
drug treatment. As controls, cells were stained with an irrelevant m6 TCR–
SA-PE tetramer (m6 specifi  cally binds to the QL9 peptide on Ld; reference 11) 
or SA-PE. Cells were subsequently analyzed by gating CD11b+ cells. 
(b) 2 × 106 MC57-SIY-Lo cells were injected s.c. into OT-1 transgenic mice 
or C3H Rag2−/− mice. After 14 d, the tumor-bearing mice were treated 
with 200 μg/g gemcitabine i.p., followed by adoptive transfer of 5 × 106 
preactivated 2C T cells at day 16 or 18. The tumor-bearing control 
mice received 5 × 106 preactivated 2C T cells at day 16 without drug 
treatment. Each symbol represents an individual mouse. Data shown 
(a and b) are representative of two similar experiments. MFI, mean fl  uo-
rescence intensity.54  INDUCED SENSITIZATION OF TUMOR STROMA | Zhang et al.
applicable to established cancers in humans, as long as at least 
some sensitivity on chemotherapy or irradiation is present. 
Our experiments involved T cells transferred into the immuno-
compromised hosts, and there has been major progress in the 
development of human T cells suitable for adoptive cellular 
immunotherapy, particularly when used in a lymphopenic 
host environment (27); thus, monospecifi  c TCR gene trans-
duction of autologous T cells transferred into lymphode-
pleted patients (28) has become feasible. Our study shows 
that combination therapy is not simply based on adding two 
procedures, each of which kills cancer cells, but rather de-
pends on taking advantage of a network of reactions   requiring 
each component to be adjusted, for specifi  c reasons, to optimal 
amounts, sequences, and timing.
MATERIALS AND METHODS
Mice, cell lines, and reagents. C57BL/6 Rag1−/− mice were purchased 
from the Jackson Laboratory. M. Mescher (University of Minnesota, Twin 
Cities, MN) provided the OT-1 mice. The 2C Rag1−/− mice were pro-
vided by J. Chen (Massachusetts Institute of Technology, Boston, MA). 
Cultured cancer cells were trypsinized and washed once with plain DMEM, 
and 2 × 106 cells were injected s.c. under the shaved back of mice. The 
  tumor size was determined at 3-d intervals. Tumor volumes were measured 
along three orthogonal axes (a, b, and c) and calculated as tumor volume = 
abc/2. Animal experiments were approved by the Institutional Animal Care 
and Use Committee at the University of Chicago. P. Ohashi (University of 
Toronto, Toronto, Canada), with the permission of H. Hengartner (University 
Hospital, Zurich, Switzerland), provided the MC57G methylcholanthrene-
induced C57BL/6-derived fi  brosarcoma. PRO4L cells have been previously 
described (2). H. Auer and S. Meredith (University of Chicago, Chicago, IL) 
synthesized the 2C-recognized peptide, SIY, and the P14-recognized peptide 
lymphocytic choriomeningitis virus–derived gp33 epitope, KAVYNFATM. 
All antibodies were purchased from BD Biosciences. Sorbitol was pur-
chased from Sigma-Aldrich. J744 Kb cells were provided by C.-R. Wang 
(University of Chicago, Chicago, IL).
Generation of SIY and gp33 vectors and transfection/transduction of 
cells. The generation of iSIY-LEGFP, igp33-LEGFP, MFG-SIY- EGFP, and 
MFG-gp33-EGFP vectors was previously described (7–9). MC57G was trans-
fected with MerCreMer to generate MC57-Neo (Neo). Neo was transfected 
with iSIY-LEGFP or igp33-LEGFP, selected with 5 μg/ml puromycin, and 
cloned by limiting dilution to generate MC57-SIY-Lo or MC57-gp33-Lo, 
respectively. MC57-SIY-Lo or MC57-gp33-Lo cells were treated with 200 nM 
4-hydroxytamoxifen for 4 d to generate MC57-SIY-Hi or MC57-gp33-Hi, 
respectively. Phoenix cells were transfected with pLEGFP, MFG-SIY-EGFP, 
or MFG-gp33-EGFP using Superfect (QIAGEN). Supernatants were used to 
infect PRO4L cells to generate PRO4L-EGFP, PRO4L-SIY-EGFP, or 
PRO4L-gp33-EGFP cell lines. PRO4L-EGFP and PRO4L-gp33-EGFP 
were used as controls for the eff  ect of EGFP expression on tetramer staining.
Preparation of single-cell suspensions from murine tumors. Tumors 
were surgically excised under sterile conditions and placed in RPMI 1640 
containing 1% antibiotic/antimycotic on ice, washed with PBS, minced into 
1–2-mm pieces, and centrifuged at 1,800 rpm for 10 min, and supernatants 
were removed. After repeating this centrifugation, the tumor fragments were 
incubated for 45 min to 1 h in a digestion solution (5 ml/g tissue) containing 
1 mg/ml trypsin, 1 mg/ml collagenase D, and 0.25 mg/ml DNase I in HBSS 
in an atmosphere of 5% CO2 at 37°C. Pipetting of the samples every 15 min 
substantially enhanced tissue disruption. DMEM containing 10% FCS and 
1% antibiotic/antimycotic was added to the cell suspension to stop the enzy-
matic activity. To lyse red blood cells, the tissue digests were briefl  y exposed 
to cold Tris NH4Cl, washed, and fi  ltered through a 70-μm nylon fi  lter mesh, 
resulting in a single-cell suspensions.
Expression, purifi  cation, and multimerization of single-chain TCR. 
High affi     nity TCR 2C-m67 was generated previously, using in vitro–
  directed evolution and yeast display (10). In brief, site-directed mutations in 
fi  ve successive codons of the CDR3α region (wild-type sequence GFASA) 
were introduced into the 2C single-chain TCR gene (Vβ-linker-Vα), and 
a library of mutants was expressed on the surface of the yeast. High affi   nity 
mutants were isolated by fl  uorescence-activated cell sorting using tetramers 
of the ligands SIYR-Kb and dEV8-Kb. Isolates with the CDR3α sequence 
LERPY were isolated from selections with both ligands. The 2C-m67 TCR 
that contained this CDR3α sequence was produced in soluble form and 
shown by various methods, including surface plasmon resonance, to have 
a dissociation constant value of 16 nM, a 2,000-fold increase compared with 
the wild-type 2C TCR (10).
Single-chain high-affi   nity TCR 2C-m67 containing a C-terminal 15-aa 
biotin substrate was cloned into pET-28a and expressed in Escherichia coli 
BL21 (DE3) cells (Stratagene), together with a plasmid containing the gene 
for the expression of BirA ligase enzyme (provided by J. Cronan, University 
of Illinois, Urbana, IL). Coexpression resulted in the in vivo biotinylation of 
the single-chain TCR. Inclusion bodies that contained the single-chain 
TCR were solubilized in 3 M urea and guanidine HCl and refolded as previ-
ously described (29). Ni-NTA agarose (QIAGEN) was used to isolate the 
single-chain TCR, followed by size exclusion chromatography (Sephacryl 
S-200; GE Healthcare). Tetramerization of single-chain TCR was performed 
by the gradual addition of SA-PE (BD Biosciences) in aliquots to saturate its 
binding sites to a total biotin-conjugated m67 single-chain TCR/SA molar 
ratio of 20:1 (to ensure formation of tetrameric complexes).
TCR tetramer staining and peptide-binding assay. In tumor stromal 
experiments, samples were preincubated with 2.4G2 to block antibody 
binding to the Fc receptors. The CD11b+ stromal cells were positively se-
lected from collagenase-digested tumors using CD11b MicroBeads (Miltenyi 
Biotec). The CD11b marker was expressed by 75–80% of the purifi  ed cells. 
For tetramer staining, 106 fresh cultured cancer cells, purifi  ed CD11b+ stro-
mal cells, or tumor single-cell suspensions were incubated with 0.86 μg 
SIY-Kb–specifi  c m67 TCR tetramer in 100 μl of staining buff  er in conjunc-
tion with mAb CD11b-APC. Cells were stained for 45 min to 1 h at room 
temperature. Cells stained with SA-PE or the molar equivalent amounts of 
PE-conjugated m6 TCR tetramer (specifi   cally binding to QL9-Ld) (11) 
were used as controls. Background fl  uorescence intensity was similar to that 
of the unstained cells (unpublished data). For the binding assay, 5 × 105 T2 
Kb cells were incubated with the SIY or gp33 peptides at diff  erent concen-
trations (0.1–1,000 nM) for 2 h at 37°C and 5% CO2 and stained with the 
SIY-Kb–specifi  c m67 TCR tetramer m67 for 1 h at room temperature. For 
Ag cross-presentation assays in vitro, purifi  ed tumor-derived CD11b+ stro-
mal cells, PECs induced by thioglycollate, J744 Kb cells, or Jaws II cells (2 × 
105 cells/well) were incubated in 48-well plates at 37°C overnight. An equal 
number of either apoptotic (sorbitol-treated) or necrotic (three consecutive 
freeze-thaw cycles) PRO4L-EGFP and PRO4L-SIY-EGFP cells were 
added as Ag donor cells and coincubated at 37°C. At the times indicated in 
the fi  gures, cells were harvested using the plunger of a 1-ml syringe as a rub-
ber policeman and analyzed by FACS for binding of the SIY-Kb–specifi  c 
m67 TCR tetramers. To exclude the possible interference of EGFP-positive 
cells, the cells were analyzed by gating the CD11b+ population (tumor-
  derived stromal cells, J744 Kb cells, or PECs) or EGFP-negative cells (Jaws II 
cells). Samples were analyzed on a FACSCalibur (BD Biosciences), and data 
were analyzed with FlowJo software (TreeStar, Inc.).
51Cr release assay. To generate cytolytic 2C T cells, 106 Tris NH4Cl−–
treated splenocytes from a 2C Rag1−/− mouse were stimulated with 6 × 106 
NH4Cl-treated, irradiated (20 Gy) splenocytes from a BALB/c mouse 
in a 15-ml rounded bottom tube (BD Biosciences) containing 3 ml RPMI 
1640 with 25 mM HEPES supplemented with 10% fetal calf serum, 2 mM 
l-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 
50 μM β-mercaptoethanol, 50 U/ml penicillin, and 50 μg/ml streptomycin. 
After 5 d, 51Cr release assays were performed as previously described (7, 8).JEM VOL. 204, January 22, 2007  55
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Adoptive transfer of T cells. For transfer of activated cells, 5 × 106 
NH4Cl-treated splenocytes from 2C transgenic mice were stimulated with 
10 μM of the SIY peptide for 3–4 d. Activation was confi  rmed by the up-
regulation of CD44 on the specifi  c T cells. The preactivated T cells were 
  injected i.v. into the retroorbital plexus in a 0.1-ml volume.
Local tumor irradiation and systemic chemotherapy. Mice were irradi-
ated using an x-ray generator (PCM 1000; Pantak) at a dose of 10 Gy. Each 
mouse was confi  ned to a lead cover with its tumor-bearing fl  ank exposed 
through an opening on the side, allowing the tumor to be irradiated locally. For 
systemic chemotherapy, tumor-bearing mice were injected i.p. with 200 μg/g 
body weight gemcitabine (Eli Lilly and Company) 14 d after tumor challenge.
Online supplemental material. Fig. S1 illustrates the sensitivity of 
SIY-Kb–specifi  c TCR tetramer binding to RMA-S cells. Fig. S2 shows that 
PRO4L-SIY-EGFP cells express high levels of the SIY Ag comparable to 
those expressed by MC57-SIY-Hi cells. Fig. S3 shows characterization of 
tumor-derived CD11b+ cells. Fig. S4 shows that APCs cross-present Ag 
from dead cancer cells rapidly and transiently. Fig. S5 shows that local radia-
tion of tumors increases the Ag cross-presentation of stromal cells in a dose-
dependent manner. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20062056/DC1.
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